Menthol Crystal Vapor Inhalation In The Prevention And Remission Of Early Diagnosed Covid-19 Patients: Evidence Based

Abstract

Purpose: The objectives of our study was to describe the effective use of menthol crystal vapor inhalationin the remission of the symptoms of COVID-19 patients (inclusive of the reversion of the positive status to negative) and to establish the preventive role that menthol plays as it relates to the transmission of the COVID-19 virus. Patients and Methods: These are clinical observational studies carried out in Jamaica between April 2020 to June 2021 at the Faculty of Dentistry of the International Postgraduate Medical College, Montego Bay Jamaica.We reported two (2) studies which includes: Study 1: A single-centre open label therapeutic trial study which comprise of four (4) elderly patients between the age of 67 years and 83 years with an average age of 77 years. Each patient was consecutively included in the study within 24-hours post positive testing for COVID-19 and placed on a menthol crystal Inhalation regimen (MCIR) for three to four days consistently, then tested on the third or fourth dayafter the commencement of the regimen. The immediate effect of menthol crystal inhalation on the oxygen saturation of three out of the four patients was also documented. All these elderly patients were symptomatic prior to the PCR testing.An additional group of three younger (middle age) patients of age range of between 35 and 49 and average age 41.3 Years were also consecutively included in this study.Again, each patient was included in the study less than 24 hours after a positive testing for COVID-19 and placed on a menthol crystal Inhalation regimen (MCIR) with one patient tested after 4-days, the second patient tested after 3-days, and the third patient tested after 2-days. In Study 2 (the prevention study of menthol crystals), the prolonged utilization of menthol in a dental practice for 14-months with the aim of preventing COVID-19, in both the patients and dental health care worker. Results: In study 1, all the four elderly patients became negative after four (4) days of use of menthol crystal with all the initial symptoms subsiding completely within this period. One elderly patient with progressive memory loss regained her memory fully at about the eight (8th) day post commencement of the MCIR. Similarly, each of the three younger patients became negative after the use of the regimen at 2 days, 3 days, and 4 days respectively. Finally in study 2, none of the 1516 patients seen at the mentholated dental clinic and 9 dental healthcare workers employed during this period contacted COVID-19 up to 2 to 3 months after attending the dental clinic for treatment, thus confirming the protection offered by our continuously mentholated environment. Conclusion: The periodic inhalation of menthol crystal utilizing the MCIR has been found to be therapeutic for COVID-19 patients. These studies are also confirmatory of the preventive role of menthol crystal inhalation for COVID-19 when it is used in the MCIR or by making the working area mentholated. The hallmark of this original work is that the menthol vapor is capable of incapacitating the COVID-19 virus and by extrapolation the emerging variants that will eventually emerge in the future.